Circulating isomiRs: a novel approach to biomarkers for epilepsy.
The study aiming to identify changes in isomiR expression in blood, utilizing a multidisciplinary approach of state‐of‐the art techniques, and determine which of these circulating molecules are biomarkers for epilepsy.
Innovation, Diagnostics, Human R&D, Project Management
Top Consortia for Knowledge and Innovation funding via Epilepsiefonds – Grant ID LSHM17051-SGF
1 January 2018 to 31 December 2020
Almost 50 million people suffer from epilepsy, making it to one of the most common neurological diseases worldwide. Intractable epilepsy has a life‐long effect on social and cognitive functioning and quality of life of patients. One of the major challenges in epilepsy research is the identification of reliable biomarkers that can be measured routinely in easily accessible samples, such as blood. Biomarkers could substantially improve the management of people with epilepsy and could lead to prevention in the right person at the right time. The Academic Medical Center and GenomeScan proposed that circulating isomiRs (recently discovered disease modified small non‐coding RNA molecules) in blood reflect pathological changes in brain and could be used as biomarkers for epilepsy. This project was designed to test this hypothesis by a use of an innovative and translational experimental approach, involving an experimental model of epilepsy as well as blood and resected brain tissue from patients with intractable epilepsies. In order to identify biomarkers, the changes of circulating isomiRs in two cohorts (developing epilepsy or no epilepsy) were studied, using state‐of‐the‐art techniques.
This work was funded by the Epilepsiefonds , with a project number LSHM17051-SGF.